Navigation Links
Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board
Date:12/15/2009

e activation of naive T cells in vivo. He is a leader in this area of research.

In April 2009, he was the recipient of a Bill and Melinda Gates Foundation grant to study exosomes as a potential TB vaccine. He received one of only 81 grants funded from over 3,000 applicants. Dr. Schorey's recent work on exosomes released from TB infected macrophages has demonstrated that these exosomes containing antigenic components of tuberculosis can be utilized for efficient antigen presentation and could provide a practical strategy in the development of a vaccine for TB.

About Dr. Wayne Comper

Dr. Comper is one of the founders, Director and Chief Science Officer of Exosome Diagnostics, Inc. Prior to Exosome Diagnostics, Dr. Comper was Chief Science Officer of AusAm Biotechnologies, Inc., a biotechnology company developing diagnostics and therapeutics to identify and treat kidney, cardiovascular and infectious diseases. Between 1991 and 2004, Dr. Comper was Reader of Biochemistry and Molecular Biology at Monash University, Clayton, Victoria, Australia. From 1974 to 1976, Dr. Comper was a postdoctoral fellow at Northwestern University Medical School in Chicago. From 1976 to 1978, he was a visiting scientist in the Department of Medical and Physiological Chemistry, Uppsala University, Sweden. In 1988, he was a Visiting Professor, Nephrology Section, Rush Medical School, Chicago, Illinois. He is the recipient of the 1992 Silver Jubilee Prize for Research at Monash University, where he also holds a Doctor of Science Degree. He has published over 170 research articles in peer-reviewed international journals. His research has attracted grants from the National Health and Medical Research Council of Australia, the Diabetes Foundation of Australia, The Australian Kidney Foundation and the Juvenile Diabetes Foundation International.

Dr. Comper and his team at Exosome Diagnostics are studying biomarkers, including genetic signatures creat
'/>"/>

SOURCE Aethlon Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Aethlon Medical Announces Data Supported Strategy to Increase Hepatitis-C (HCV) Cure Rates
2. Aethlon Medical, Inc. Announces Annual Meeting Results
3. Aethlon Medical to Present at LD MICRO Conference on December 3, 2009
4. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
5. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
6. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
7. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
8. BioMS Medical announces its intention to renew a normal course issuer bid
9. Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group
10. ATS Medical Expands Open Pivot Heart Valve Offerings
11. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... , May 20, 2015  Health eCareers, ... short-staffed healthcare organizations with job seekers looking for ... , a new mobile and online tool dedicated ... healthcare industry. SHIFT enables employers to ... tenens, travel nursing, per diem and other temporary ...
(Date:5/20/2015)... 2015  Haemonetics Corporation (NYSE: HAE ) announced ... will present at The Jefferies 2015 Global Healthcare Conference ... 1 st , 2015 at 8:30am Eastern time.  ... live via webcast at: http://wsw.com/webcast/jeff88/hae ... ) is a global healthcare company dedicated to providing ...
(Date:5/20/2015)... Research and Markets ( http://www.researchandmarkets.com/research/hdsx2f/bone ... "Bone Morphogenetic Proteins Market (Types : rhBMP-2 and ... - Maxillofacial) - Global Industry Analysis, Size, Share, ... report to their offering. The global ... the types of recombinant BMPs, applications, and geography. ...
(Date:5/20/2015)... The Greater Gift Initiative, Inc ... pleased to announce they are donating 10,010 vaccines today ... represent the effort and commitment of clinical trial volunteers ... sites in 2014. , With a mission to ... clinical trial participation, GGI supports International Clinical Trials Day ...
Breaking Biology Technology:Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 2Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 3Global Bone Morphogenetic Proteins Market Industry Analysis 2014 - 2022 2The Greater Gift Initiative Donates over 10,000 Vaccines in Honor of International Clinical Trials Day 2
... ... 2008 -- Facilitating the entry of Bluetooth into the ... effortlessly examine not only the wireless interface between devices, such as ... between the device CPU and the Bluetooth chip inside the device. ...
... SEATTLE, Dec. 16 The Washington Life Sciences Discovery,Fund ... start-up phase of,the Washington Vaccine Alliance (WAVA) and to ... herpes and syphilis. Announced today, the,grant is funded by ... this innovative new organization to,life. , ...
... Colo.,Dec. 16 Bolder BioTechnology, Inc. today announced that ... Small Business Innovation Research (SBIR) grant from the National ... National Institutes of Health (NIH). The grant will ... studies of the company,s proprietary long-acting growth hormone product, ...
Cached Biology Technology:Newly Available To Medical Device Manufacturers - Bluetooth Testing Equipment 2Newly Available To Medical Device Manufacturers - Bluetooth Testing Equipment 3Life Sciences Discovery Fund Awards $4.7 Million to Support New Vaccine Program 2Life Sciences Discovery Fund Awards $4.7 Million to Support New Vaccine Program 3Life Sciences Discovery Fund Awards $4.7 Million to Support New Vaccine Program 4Bolder BioTechnology Receives $1.9 Million NIH Grant to Continue Development of Long-Acting Growth Hormone Product 2
(Date:5/11/2015)... May 11, 2015 Curemark LLC, a privately ... of a new Phase III double blind, randomized, placebo-controlled ... formulation, CM-AT, on all children ages 3-8 with Autism. ... Phase III double blinded clinical trial for CM-AT in ... of the digestive enzyme chymotrypsin. This new trial will ...
(Date:5/6/2015)... Israel , May 6, 2015 LifeBEAM, ... most established helmet producer, announced today that they will ... Helmet, the world,s first bio-sensing cycling helmet and the ... released in two new colors in order to give ... the product. In addition, LifeBEAM and Lazer announced their ...
(Date:4/27/2015)... FORT LAUDERDALE, Fla. , Apr. 27, 2015 /PRNewswire/ ... provider of access control and security systems is pleased ... joined the company as a consultant and member of ... Bedore is widely known as a thought leader ... Socrates Distance Learning Technology Group, and has published studies ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4
... to be a godsend for many of the two ... its downside. People on the drug may develop hypothyroidism, ... gain weight. , However, better treatments for bipolar disorder ... by which lithium damps the highs and lows of ...
... they see colors when viewing letters and numbers really ... of the University of California San Diego, have found. ... brains reveals that they show activation of color-perception areas. ... the hypothesis that the condition is due to cross-activation ...
... have found a way of stimulating the immune ... cause the devastating plaques,that are characteristic of Alzheimer's ... using a,protein-based vaccine to slow the progression of ... have created a gene-based,vaccine aimed at stimulating the ...
Cached Biology News:Beyond lithium for bipolar disorder 2New insight into people who 'see' colors in letters and numbers 2Gene vaccine for Alzheimer's disease shows promising results 2
Goat polyclonal to SART1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: GSSKKHRGEKEAA, corresponding to N terminal amino acids 2-14 of Human SART1. Entrez Gene ID: 909...
...
Rabbit polyclonal to SpUlp2 ( Abpromise for all tested applications). Antigen: Synthetic peptide: SNNERQSLSSGSND, corresponding to amino acids 622-635 of Schizosaccharomyces pombe SpUlp2...
Request Info...
Biology Products: